Health Care & Life Sciences » Biotechnology | Intercept Pharmaceuticals Inc.

Intercept Pharmaceuticals Inc. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
1,621.60
1,741.60
2,782.00
24,951.00
130,956.00
179,804
Cost of Goods Sold (COGS) incl. D&A
-
-
-
-
5,972.00
7,101
Gross Income
-
-
-
-
124,984.00
172,703
SG&A Expense
40,967.70
114,469.00
230,247.00
378,658.00
455,396.00
458,193
EBIT
39,451.70
113,170.20
229,156.00
357,538.00
330,412.00
285,490
Unusual Expense
28,441.10
170,831.90
-
45,000.00
5,200.00
-
Non Operating Income/Expense
100.40
776.10
2,727.00
3,904.00
4,516.00
6,771
Interest Expense
-
-
-
14,196.00
29,271.00
30,523
Pretax Income
67,792.40
283,226.00
226,429.00
412,830.00
360,367.00
309,242
Consolidated Net Income
67,792.40
283,226.00
226,429.00
412,830.00
360,367.00
309,242
Net Income
67,792.40
283,226.00
226,429.00
412,830.00
360,367.00
309,242
Net Income After Extraordinaries
67,792.40
283,226.00
226,429.00
412,830.00
360,367.00
309,242
Net Income Available to Common
67,792.40
283,226.00
226,429.00
412,830.00
360,367.00
309,242
EPS (Basic)
3.76
13.63
9.56
16.74
14.38
10.86
Basic Shares Outstanding
18,028.70
20,784.40
23,694.20
24,663.00
25,054.00
28,464
EPS (Diluted)
3.76
13.63
9.56
16.74
14.38
10.86
Diluted Shares Outstanding
18,028.70
20,784.40
23,694.20
24,663.00
25,054.00
28,464
EBITDA
39,346.00
112,727.40
227,465.00
353,707.00
325,811.00
280,908

About Intercept Pharmaceuticals

View Profile
Address
10 Hudson Yards
New York New York 10001
United States
Employees -
Website http://www.interceptpharma.com
Updated 07/08/2019
Intercept Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of novel therapeutics in treating chronic liver diseases. Its product pipeline is OCALIVA which is used for the treatment of primary biliary cholangitis, nonalcoholic steatohepatitis, primary sclerosing cholangitis, and biliary atresia. The company was founded by Mark E.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.